Physician profile
Padmini Nathan
NPI 1861550592
$198,678.63
in general payments reported to CMS, 2019-2025
25 companies · $573 in 2025
The $573 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $84K · 2021: $40K · 2022: $72K · 2023: $838 · 2024: $667 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Entertainment: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.26 |
| Entertainment | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $194,218.74 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $870.53 | 2022-2025 | Infuse, Miebo, Infuse Multifocal |
| Alcon Vision LLC | $649.65 | 2019-2025 | Tryptyr, Total30, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $413.74 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $350.95 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $341.68 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $313.53 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $238.32 | 2019-2023 | |
| Coopervision INC. | $237.38 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Sun Pharmaceutical Industries INC. | $204.79 | 2019-2025 | Cequa |
| Allergan, INC. | $187.33 | 2021-2022 | |
| Shire North American Group INC | $149.40 | 2019 | |
| Horizon Therapeutics Plc | $109.83 | 2023 | Tepezza |
| Abb Con-Cise Optical Group LLC | $91.35 | 2020 | |
| Kala Pharmaceuticals, INC. | $55.83 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oasis Medical, INC. | $49.27 | 2020-2023 | Oasis Tears |
| Maculogix, INC. | $41.13 | 2020 | |
| Dompe US, INC. | $31.56 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $21.62 | 2019 | |
| Thea Pharma INC. | $20.06 | 2022 | |
| Harrow Eye, LLC | $18.73 | 2024 | Vevye |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.59 | 2022 | |
| Abbvie INC. | $15.38 | 2022 | |
| Optos, INC. | $14.00 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmini Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.